Zhejiang Kanying Import & Export Co. Ltd 86--17169758851 kanyingexport@gmail.com
Purity 99% CAS 137862-53-4 Valsartan Powder Treat High Blood Pressure

Purity 99% CAS 137862-53-4 Valsartan Powder Treat High Blood Pressure

  • High Light

    CAS 137862-53-4 Valsartan Powder


    High Blood Pressure Valsartan Powder


    Purity 99% Valsartan

  • Product Title
  • Brand Name
    Kan Ying
  • Purity
  • Appearance 
    White Or Off-white Powder,
  • CAS No
  • Boiling Point
    684.9±65.0 °C At 760 MmHg
  • Melting Point
  • Flash Point
    368.0±34.3 °C
  • Storage
    Cool Dry Place
  • Shelf Life
    2 Years
  • Place of Origin
  • Brand Name
    Kan Ying
  • Minimum Order Quantity
  • Price
    To discuss
  • Packaging Details
  • Delivery Time
  • Payment Terms
    L/C, D/A, D/P, T/T, Western Union, MoneyGram,Dollars
  • Supply Ability

Purity 99% CAS 137862-53-4 Valsartan Powder Treat High Blood Pressure

Valsartan CAS 137862-53-4 White or off-white powder Treat high blood pressure


1. Product title:Valsartan


2. Product parameter table:


Product Name Valsartan Specification 99%
Appearance  White or off-white powder, CAS No 137862-53-4
Brand Name Kan Ying Store-method Cool Dry Place
Shelf Life 2 Years When
Properly Stored
From India



3. Product Description:Valsartan is an angiotensin II receptor antagonist antihypertensive drug. The drug can block the type I (AT1) receptor of angiotensin II, increase the plasma level of angiotensin II and stimulate The unblocked AT2 receptor also counteracts the role of the AT1 receptor, thus achieving the effect of dilating blood vessels and lowering blood pressure. In the United States, Valsartan is a drug used to treat hypertension, congestive heart failure, and post-myocardial infarction. The Divin Valsartan developed and produced by Ciba-Geigy of Switzerland obtained the relevant patent rights in the United States and Europe in 1995 and 1996 respectively, and was listed in Germany for the first time in July 1996, and has been successively launched in Europe, the United States, and Japan since then. Listed. Ciba-Geigy and Sandoz merged in 1996 to form Novartis. Valsartan has the characteristics of long-lasting and stable blood pressure lowering effect and small side effects [1].


4.Chemical properties:

Density 1.2±0.1 g/cm3
Boiling point 684.9±65.0 °C at 760 mmHg
Melting point 116-117°C
Molecular formula C24H29N5O3
Molecular weight 435.519
Flash point 368.0±34.3 °C
Accurate quality 435.227051
PSA 112.07000
LogP 4.75
Appearance: white crystalline powder
Vapor pressure 0.0±2.2 mmHg at 25°C
Refractive index 1.587
Storage conditions -20°C Freezer, Under inert atmosphere
Stability Hygroscopic
Molecular Structure
1. Molar refractive index: 120.62
2. Molar volume (cm3/mol): 359.1
3. Isotonic specific volume (90.2K): 978.0
4. Surface tension (dyne/cm): 55.0
5. Polarizability (10-24cm3): 47.81
Computational Chemistry
1. Hydrophobic parameter calculation reference value (XlogP): 4.4
2. Number of hydrogen bond donors: 2
3.Number of hydrogen bond acceptors: 6
4. Number of rotatable chemical bonds: 10
5. Number of tautomers: 2
6. Topological molecular polar surface area 112
7. Number of heavy atoms: 32
8.Surface charge: 0
9. Complexity: 608
10. Number of isotope atoms: 0
11.Determine the number of atomic stereocenters: 1
12. Uncertain the number of atomic stereo centers: 0
13.Determine the number of chemical bond stereo centers: 0
14. Uncertain the number of chemical bond stereo centers: 0
15.Number of covalent bond units: 1
5. use:Antihypertensive drugs. Valsartan is an angiotensin Ⅱ (Ang Ⅱ) receptor antagonist, which can selectively block the binding of Ang Ⅱ and AT1 receptor (its specific antagonistic effect on AT1 receptor is about 20,000 times greater than AT2), thereby inhibiting vasoconstriction The release of aldosterone and aldosterone produces a hypotensive effect [1].



6. Precautions:1. (1) Angioedema. (2) Aortic valve or left atrioventricular valve stenosis. (3) Cholestasis or bile duct obstruction. (4) Lactation period. (5) Coronary artery disease. (6) Old age. (7) Liver dysfunction. (8) Hypertrophic cardiomyopathy. (9) Hyponatremia or decreased blood volume, such as high-dose diuretics. (10) Unilateral or bilateral renal artery stenosis. (11) Surgical patients requiring general anesthesia.
2. Patients taking medicine should pay attention to driving and operating machinery.
3. The dosage of administration must follow the principle of individualization, and adjust the dosage according to the effect.
4. Patients with severe sodium deficiency and/or blood volume insufficiency, such as patients taking large doses of diuretics, may occasionally experience symptomatic hypotension with valsartan. Therefore, the patient's hyponatremia and hypovolemia should be corrected before treatment.
5. If there is laryngeal stridor or angioedema of the face, tongue or glottis, the drug should be discontinued.
6. There is no experience of overdose of valsartan. The main symptoms of overdose are obvious hypotension, which can be treated with emesis and intravenous infusion of normal saline if necessary. Hemodialysis cannot be removed.


7. Pictures of the product:

Purity 99% CAS 137862-53-4 Valsartan Powder Treat High Blood Pressure 0Purity 99% CAS 137862-53-4 Valsartan Powder Treat High Blood Pressure 1







Clobetasol propionate